TETRAPHASE PHARMACEUTICALS I's ticker is TTPHXXXX and the CUSIP is 88165N105. A total of 91 filers reported holding TETRAPHASE PHARMACEUTICALS I in Q2 2016. The put-call ratio across all filers is 1.46 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2018 | $77,000 | -24.5% | 28,017 | -1.7% | 0.00% | 0.0% |
| Q2 2018 | $102,000 | +9.7% | 28,492 | -6.4% | 0.00% | 0.0% |
| Q1 2018 | $93,000 | -58.1% | 30,432 | -13.7% | 0.00% | -50.0% |
| Q4 2017 | $222,000 | +117.6% | 35,259 | +31.9% | 0.00% | +100.0% |
| Q3 2016 | $102,000 | -25.0% | 26,732 | -15.7% | 0.00% | -50.0% |
| Q2 2016 | $136,000 | -6.2% | 31,696 | +1.2% | 0.00% | 0.0% |
| Q1 2016 | $145,000 | -58.2% | 31,313 | -9.6% | 0.00% | -50.0% |
| Q4 2015 | $347,000 | +48.9% | 34,643 | +10.9% | 0.00% | +33.3% |
| Q3 2015 | $233,000 | -85.3% | 31,227 | -6.6% | 0.00% | -86.4% |
| Q2 2015 | $1,586,000 | +45.5% | 33,428 | +12.4% | 0.02% | +69.2% |
| Q1 2015 | $1,090,000 | +5.9% | 29,736 | +14.8% | 0.01% | +8.3% |
| Q4 2014 | $1,029,000 | +609.7% | 25,905 | +141.1% | 0.01% | +500.0% |
| Q2 2014 | $145,000 | -6.5% | 10,745 | -24.4% | 0.00% | 0.0% |
| Q1 2014 | $155,000 | – | 14,207 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| HARVEY CAPITAL MANAGEMENT INC | 293,675 | $14,061,000 | 4.76% |
| BB BIOTECH AG | 1,507,114 | $71,497,000 | 1.94% |
| SECTORAL ASSET MANAGEMENT INC | 893,076 | $42,368,000 | 1.77% |
| Opaleye Management Inc. | 65,000 | $3,084,000 | 1.23% |
| COLUMBIA PARTNERS L.L.C. INVESTMENT MANAGEMENT | 390,294 | $18,515,000 | 1.14% |
| Granite Point Capital Management, L.P. | 75,206 | $3,568,000 | 1.04% |
| Granahan Investment Management | 705,601 | $33,474,000 | 0.95% |
| Iguana Healthcare Management, LLC | 50,000 | $2,372,000 | 0.75% |
| Eventide Asset Management | 290,000 | $13,758,000 | 0.74% |
| Rhenman & Partners Asset Management AB | 107,400 | $5,095,000 | 0.61% |